Milan-based biopharmaceutical company Olon has announced it will be supporting Dutch biotech CimCure BV's Phase I clinical manufacturing of a novel cancer vaccine.
CimCure's formulation includes a squalene-based adjuvant and under the agreement, Olon will be responsible for the aseptic filling of the adjuvant into amber-coloured glass bottles.
This is crucial for ensuring product quality and compliance for early-stage clinical trials.
"Partnering with Olon allows us to leverage deep expertise in complex formulation handling and aseptic manufacturing," said Joost van Bree, CMO at CimCure BV.
Their capabilities are instrumental in supporting the successful progression of our vaccine into clinical development.
Manufacturing oil-based and light-sensitive formulations presents technical challenges, including viscosity issues and stringent aseptic processing requirements.
Olon said in its statement that the company will bring its expertise and technology to effectively manage these complexities within a compliant regulatory framework.
"We are proud to support CimCure BV in advancing this promising cancer vaccine candidate," said Andrea Conforto, S&M – VP CDMO Biotech, Olon.
This collaboration highlights our commitment to enabling innovative therapies through flexible and high-quality manufacturing solutions.
The pair stated that the new agreement represents the first step in a broader collaboration between the two companies, with the potential to extend into later stages of clinical development as the programme progresses.